clopidogrel acino pharma gmbh
acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.
esomeprazole teva pharma 20 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 20 milligram - proton pump inhibitors
esomeprazole teva pharma 40 milligram tablets gastro-resistant
teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors
omeprazole teva pharma 10 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule - 10 milligram(s) - proton pump inhibitors; omeprazole
omeprazole teva pharma 20 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule - 20 milligram(s) - proton pump inhibitors; omeprazole
omeprazole teva pharma 40 mg gastro-resistant capsules, hard
teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole
voriconazole pharma regulatory solutions 200 milligram pdr for soln for infusion
pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
clopidogrel 1a pharma
acino pharma gmbh - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.
clopidogrel acino pharma
acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.
digoxin kern pharma 0.25 mg
trima israel pharmaceutical products maabarot ltd - digoxin - tablets - digoxin 0.25 mg - digoxin - cardiac failure:digoxin kern pharma is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. the greatest therapeutic benefit is achieved in patients with ventricular dilatation.digoxin kern pharma is specifically indicated where cardiac failure is accompanied by atrial fibrilation.supraventricular arrhythmias:digoxin kern pharma is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.